| 000 | 01862 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517155336.0 | ||
| 264 | 0 | _c20180717 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1538-8514 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-16-0602-T _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoth, Gaël S | |
| 245 | 0 | 0 |
_aEfficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _c10 2017 |
||
| 300 |
_a2157-2165 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAminopyridines _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aLiver Cirrhosis _xdrug therapy |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xadministration & dosage |
| 650 | 0 | 4 |
_aOncogene Protein v-akt _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPhenylurea Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aSorafenib |
| 700 | 1 | _aMacek Jilkova, Zuzana | |
| 700 | 1 | _aZeybek Kuyucu, Ayca | |
| 700 | 1 | _aKurma, Keerthi | |
| 700 | 1 | _aAhmad Pour, Séyédéh Tayébéh | |
| 700 | 1 | _aAbbadessa, Giovanni | |
| 700 | 1 | _aYu, Yi | |
| 700 | 1 | _aBusser, Benoit | |
| 700 | 1 | _aMarche, Patrice N | |
| 700 | 1 | _aLeroy, Vincent | |
| 700 | 1 | _aDecaens, Thomas | |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 16 _gno. 10 _gp. 2157-2165 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-16-0602-T _zAvailable from publisher's website |
| 999 |
_c27231375 _d27231375 |
||